Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial

Stephan R. Targan, Brian G. Feagan, Richard N. Fedorak, Bret A. Lashner, Remo Panaccione, Daniel H. Present, Martina E. Spehlmann, Paul J. Rutgeerts, Z. Tulassay, Miroslava Volfova, Douglas C. Wolf, Chito Hernandez, Jeffrey Bornstein, William J. Sandborn

Research output: Contribution to journalArticle

488 Citations (Scopus)

Abstract

Background & Aims: A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease. Methods: Patients (N = 509) with moderately to severely active Crohn's disease and active inflammation characterized by elevated C-reactive protein concentrations were randomized (1:1) to receive natalizumab 300 mg or placebo intravenously at Weeks 0, 4, and 8. The primary end point was induction of response (≥70-point decrease from baseline in the Crohn's Disease Activity Index score at Week 8 sustained through Week 12). Additional efficacy end points included the proportion of patients with sustained remission (Crohn's Disease Activity Index score

Original languageEnglish
Pages (from-to)1672-1683
Number of pages12
JournalGastroenterology
Volume132
Issue number5
DOIs
Publication statusPublished - May 2007

Fingerprint

Crohn Disease
Placebos
Therapeutics
C-Reactive Protein
Randomized Controlled Trials
Inflammation
Natalizumab

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., ... Sandborn, W. J. (2007). Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial. Gastroenterology, 132(5), 1672-1683. https://doi.org/10.1053/j.gastro.2007.03.024

Natalizumab for the Treatment of Active Crohn's Disease : Results of the ENCORE Trial. / Targan, Stephan R.; Feagan, Brian G.; Fedorak, Richard N.; Lashner, Bret A.; Panaccione, Remo; Present, Daniel H.; Spehlmann, Martina E.; Rutgeerts, Paul J.; Tulassay, Z.; Volfova, Miroslava; Wolf, Douglas C.; Hernandez, Chito; Bornstein, Jeffrey; Sandborn, William J.

In: Gastroenterology, Vol. 132, No. 5, 05.2007, p. 1672-1683.

Research output: Contribution to journalArticle

Targan, SR, Feagan, BG, Fedorak, RN, Lashner, BA, Panaccione, R, Present, DH, Spehlmann, ME, Rutgeerts, PJ, Tulassay, Z, Volfova, M, Wolf, DC, Hernandez, C, Bornstein, J & Sandborn, WJ 2007, 'Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial', Gastroenterology, vol. 132, no. 5, pp. 1672-1683. https://doi.org/10.1053/j.gastro.2007.03.024
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH et al. Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial. Gastroenterology. 2007 May;132(5):1672-1683. https://doi.org/10.1053/j.gastro.2007.03.024
Targan, Stephan R. ; Feagan, Brian G. ; Fedorak, Richard N. ; Lashner, Bret A. ; Panaccione, Remo ; Present, Daniel H. ; Spehlmann, Martina E. ; Rutgeerts, Paul J. ; Tulassay, Z. ; Volfova, Miroslava ; Wolf, Douglas C. ; Hernandez, Chito ; Bornstein, Jeffrey ; Sandborn, William J. / Natalizumab for the Treatment of Active Crohn's Disease : Results of the ENCORE Trial. In: Gastroenterology. 2007 ; Vol. 132, No. 5. pp. 1672-1683.
@article{7da0837e92a44dcc8db42c1a76354c39,
title = "Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial",
abstract = "Background & Aims: A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease. Methods: Patients (N = 509) with moderately to severely active Crohn's disease and active inflammation characterized by elevated C-reactive protein concentrations were randomized (1:1) to receive natalizumab 300 mg or placebo intravenously at Weeks 0, 4, and 8. The primary end point was induction of response (≥70-point decrease from baseline in the Crohn's Disease Activity Index score at Week 8 sustained through Week 12). Additional efficacy end points included the proportion of patients with sustained remission (Crohn's Disease Activity Index score",
author = "Targan, {Stephan R.} and Feagan, {Brian G.} and Fedorak, {Richard N.} and Lashner, {Bret A.} and Remo Panaccione and Present, {Daniel H.} and Spehlmann, {Martina E.} and Rutgeerts, {Paul J.} and Z. Tulassay and Miroslava Volfova and Wolf, {Douglas C.} and Chito Hernandez and Jeffrey Bornstein and Sandborn, {William J.}",
year = "2007",
month = "5",
doi = "10.1053/j.gastro.2007.03.024",
language = "English",
volume = "132",
pages = "1672--1683",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Natalizumab for the Treatment of Active Crohn's Disease

T2 - Results of the ENCORE Trial

AU - Targan, Stephan R.

AU - Feagan, Brian G.

AU - Fedorak, Richard N.

AU - Lashner, Bret A.

AU - Panaccione, Remo

AU - Present, Daniel H.

AU - Spehlmann, Martina E.

AU - Rutgeerts, Paul J.

AU - Tulassay, Z.

AU - Volfova, Miroslava

AU - Wolf, Douglas C.

AU - Hernandez, Chito

AU - Bornstein, Jeffrey

AU - Sandborn, William J.

PY - 2007/5

Y1 - 2007/5

N2 - Background & Aims: A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease. Methods: Patients (N = 509) with moderately to severely active Crohn's disease and active inflammation characterized by elevated C-reactive protein concentrations were randomized (1:1) to receive natalizumab 300 mg or placebo intravenously at Weeks 0, 4, and 8. The primary end point was induction of response (≥70-point decrease from baseline in the Crohn's Disease Activity Index score at Week 8 sustained through Week 12). Additional efficacy end points included the proportion of patients with sustained remission (Crohn's Disease Activity Index score

AB - Background & Aims: A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease. Methods: Patients (N = 509) with moderately to severely active Crohn's disease and active inflammation characterized by elevated C-reactive protein concentrations were randomized (1:1) to receive natalizumab 300 mg or placebo intravenously at Weeks 0, 4, and 8. The primary end point was induction of response (≥70-point decrease from baseline in the Crohn's Disease Activity Index score at Week 8 sustained through Week 12). Additional efficacy end points included the proportion of patients with sustained remission (Crohn's Disease Activity Index score

UR - http://www.scopus.com/inward/record.url?scp=34247884424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247884424&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2007.03.024

DO - 10.1053/j.gastro.2007.03.024

M3 - Article

C2 - 17484865

AN - SCOPUS:34247884424

VL - 132

SP - 1672

EP - 1683

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -